Although the majority of factor VI1 (FVII) circulates in the zymogen form, low levels of activated factor VI1 (FVlla) have been postulated to exist in plasma and to serve a priming function for triggering of the clotting cascade. However, direct measurement of plasma FVlla has not previously been possible. W e have quantified plasma FVlla levels using a novel, highly sensitive assay that is free from interference by FVII. Specificity of this clot-based assay results from the use of a mutant tissue factor that is selectively deficient in promoting FVll activation, but retains FVlla cofactor function. In normal adults, FVIla was found to be present in plasma (mean: 3.6 ng/mL) with considerable variation be-ACTOR VI1 (FVII), the first enzyme in the extrinsic F pathway of blood coagulation, is a serine protease zymogen that is converted by limited proteolysis into FVIIa, the enzymatically active form. However, FVIIa possesses very little activity unless it is complexed with tissue factor (TF), its essential protein c~f a c t o r .~ Because FVII must be proteolytically activated to be functional, attention has focused on its mechanism of activation during initiation of the clotting cascade. A variety of plasma proteases, including factors IXa, Xa, XIIa, and thrombin, are capable of converting FVII to FVIIa, and the rate of FVII activation is enhanced dramatically in the presence of TF.5-7 Recently, FVIIa itself has been reported to activate FVII in the presence of TF.8 Termed FVII autoactivation, this process has been proposed as an additional means by which active TFFVIIa complexes can be gene~-ated.~>~ Although the bulk of FVII circulates in the plasma in the zymogen form, certain studies have proposed that plasma of normal individuals may contain low but significant levels of FVIIa," which is hypothesized to serve a "priming" function in the initiation of the clotting ca~cade.~.~.'' In this view, low tween individuals (range: 0.5 to 8.4 ng/mL). FVlla levels were only loosely correlated with FVll coagulant activity, but were elevated in pregnancy and reduced with oral anticoagulant therapy. Incubation of plasma on ice in glass containers (cold activation) resulted in substantial FVIla generation. Measurement of plasma forms of factor VI1 is of potential clinical importance because elevated FVll coagulant activity has been implicated as a significant risk predictor for ischemic heart disease. Clinically, this new assay will now permit direct assessment of the role of plasma FVlla in thrombotic disorders.
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0 1993 by The American Society of Hematology. levels of TFFVIIa complexes would result in an initial burst of factor Xa that could feed back to activate the rest of the bound FVII, as well as initial amounts of the downstream pro-cofactors, factors V and VIII.12 Altematively, pre-existing plasma FVIIa may directly convert TF-bound FVII to FVIIa via autoactivati~n.~,~ Consistent with these hypotheses, there is no effective plasma inhibitor of free FVIIa,13 and intravenous (IV) administration of FVIIa into animals or humans has shown that it has a plasma half-life of approximately 2.5 hours." This half-life is extremely long for an activated plasma protease, and is nearly as long as the approximately 5-hour half-life of zymogen FVII.
Therefore, measurement of plasma FVIIa levels would be desirable in understanding how the clotting cascade is triggered, and would also be valuable in understanding clinical correlates of FVII(a) levels. Interestingly, elevated plasma factor VI1 coagulant activity (FVI1:C) has been reported to be a significant predictor of risk for ischemic heart disease and cardiovascular death.I4-I6 However, the previously existing FVII:C assay measures an aggregate of both FVII and FVIIa levels in plasma, and variations in assay configuration between laboratories are thought to affect its relative sensitivity to FVII versus FVIIa.I7 This has led to controversy over whether elevated levels of FVIIa per se, or of total FVII + FVIIa, are more closely tied to increased risk of disease in a given ~o n d i t i o n . '~. '~ To separately assess the roles of FVII versus FVIIa as predictors of risk for thrombotic disease, it would be desirable to have simple, reliable assays that measured only FVII or only FVIIa. Indeed, Mann17 recently summarized the lack of specificity of clotting assays for FVII/ FVIIa and pointed out the need for activity assays with much greater specificity, or at least for a clearer understanding of the performance limitations of existing assays.
Alternative methods that have proved useful for assessing the degree of activation of other coagulation proteases cannot readily be extended to FVIIa. For example, although in vivo activation of some coagulation proteases can be indirectly assessed by measuring plasma levels of the characteristic peptides released on zymogen activation?',*' proteolytic conversion of FVII to FVIIa is not accompanied by release of an activation peptide. Similarly, measurement of circulating levels of protease-inhibitor complexes, such as thrombin-antithrombin 111, cannot readily be extended to circulating FVIIa because it has no effective plasma inhibitor.13
Blood, Vol81, No 3 (February 1). 1993: pp [734] [735] [736] [737] [738] [739] [740] [741] [742] [743] [744] For personal use only. on October 22, 2017. by guest www.bloodjournal.org From Therefore, direct measurement of plasma FVIIa itself is necessary to assess the degree of FVII activation. The reason that existing assays of FVI1:C suffer from interference from zymogen FVII is that they initiate clotting with thromboplastin (the active ingredient of which is TF), and TF strongly promotes the conversion of FVII to FVIIa. A clotting assay specific for FVIIa-and free of interference by zymogen FVIIcould theoretically be devised if TF were altered so that it retained cofactor function toward FVIIa but no longer supported conversion of FVII to FVIIa. We now report the development of such a clotting assay specific for FVIIa and apparently free of interference from zymogen FVII. This simple assay uses a soluble mutant form of TF, which we recently demonstrated has selectively lost the ability to promote FVII activation, while at the same time retaining function as a cofactor for FVIIa-catalyzed activation of factor X. 9 The assay permits direct measurement of FVIIa in plasma, and should facilitate investigation into the relationship between plasma FVIIa levels and thromboembolic disease. It also provides a sensitive new way of monitoring the ongoing activation or turnover of the clotting system. In addition, the new assay should provide a rapid, quantitative means of monitoring plasma FVIIa levels in patients undergoing oral anticoagulant therapy or receiving recombinant FVIIa therapy."
MATERIALS AND METHODS
Reagents. Recombinant human FVIIa was purchased from Novo Biolabs (Danbury, CT). Human plasmas congenitally deficient in FVII or factor IX were purchased from George King Bio-Medical (Overland Park, KS). Immunodepleted FVIIdeficient human plasma was purchased from Baxter Diagnostics (Miami, FL). These deficient plasmas had less than 1% residual factor activity, according to the suppliers. Rabbit brain cephalin and mixed rabbit brain phospholipids (KC1-washed, ch1oroform:methanol extract of rabbit brain) were purchased from Sigma Chemical Co (St Louis, MO). Purified phosphatidylcholine and phosphatidylserine were purchased from Avanti Polar Lipids (Pelham, AL).
Wild-type FVII was purified from human plasma and activated to FVIIa as described? Recombinant human FVII was expressed and purified as described.' Recombinant, soluble human TF ( s T F~.~~~) was expressed in Escherichia coli and purified as described elsewhere." Bacterially expressed s T F~.~~~ consists only of the extracellular domain of TF and is comparable with recombinant s T F~.~,~ produced in mammalian cells.24 Soluble TF produced in either mammalian cells or bacteria was found to perform identically in the new soluble TF clotting assay for FVIIa described below (data not shown). Concentrations of purified sTF,.,,' were determined spectrophotometrically using an E& of 14.823 and an M, of 25,000. Wild-type human TF was purified from brain as des~ribed?~ and reconstituted into mixed rabbit brain phospholipid vesicles according to the method of Carson and KonigsbergZ6
Blood collection for this project was from volunteer donors who had given written consent, under protocols approved by the Institutional Review Boards of the University of Oklahoma Health Sciences Center and the Oklahoma Medical Research Foundation. Blood was drawn from normal healthy donors directly into sodium citrate anticoagulant using either 5 mL Monovette brand combination syringe/centrifuge tubes containing 0.5 mL 0.106 mol/ L trisodium citrate (Sarstedt, Princeton, NJ), or siliconized glass vacuum collection tubes containing buffered sodium citrate (Becton Dickinson Vacutainer Systems, Rutherford, NJ). A two-syringe colProtein puriJication.
Blood collection.
lection technique was used: venipuncture was performed using a butterfly catheter (Surflo brand winged infusion set with a siliconized 19-gauge needle; Terumo Medical Corporation, Elkton, MD) through which 5-mL samples of blood were collected sequentially into two separate Monovette syringes or Vacutainer tubes. Unless otherwise indicated, only the second collection tube was used for subsequent analysis. Platelet-poor plasma was prepared from citrated blood by centrifugation at 3,200g for 20 minutes. All handling of blood and plasma was at room temperature using polystyrene or polypropylene centrifuge tubes and pipets; the use of glass vessels or pipets was avoided. Plasma samples were either assayed fresh or were stored frozen at -70°C in plastic containers. Frozen plasma samples were thawed rapidly at 37"C, then held at room temperature until assayed. Pooled human plasma was prepared by mixing together citrated, platelet-poor plasma from 20 normal donors, and storing aliquots at -70°C in polypropylene or polystyrene tubes until used.
A stock solution of rabbit brain cephalin was prepared in normal saline according to the manufacturer's instructions (Sigma), resulting in a IO-fold concentrate ( l o x rabbit brain cephalin [RBC]) relative to the final concentration recommended by the manufacturer for use in the Partial Thromboplastin Time test. The soluble TF reagent was prepared by diluting the 1OX RBC concentrate (typically to yield 2X RBC final) with TBS/BSA (100 mmol/L NaCI, 50 mmol/L Tris.HC1, pH 7.4, 0.02% NaN3, 0.1% bovine serum albumin) containing sTF,.,,, at a level sufficient to yield the indicated final concentrations (typically 1 pmol/L sTF,. 2,9 final). Soluble TF reagent was typically stored frozen at -70°C in small aliquots and was never subjected to more than one freeze/ thaw cycle.
Phospholipid vesicles were prepared from purified phosphatidylcholine and phosphatidylserine (in a 6040 molar ratio; PCPS vesicles) or mixed brain phospholipid using either the octylglucoside dialysis method? or a modification of the method of Carson and Konigsberg26 in which the tissue factor was omitted.
Soluble TF clotting assay for FVIIa. Unless otherwise indicated, the new FVIIa assay, in either manual or automated mode, was performed using plasma samples that had been diluted IO-fold with FVII-deficient plasma (1 vol test plasma plus 9 vol FVII-deficient plasma).
The soluble TF clotting assay was performed in manual mode as follows: Polystyrene 12 X 75 mm test tubes were prewarmed in a 37°C water bath, along with a solution of 25 mmol/L CaClz made up in water. Soluble TF reagent (0.1 mL per tube) was pipetted into each test tube and allowed to warm to 37°C for at least 2 minutes. Room-temperature plasma samples (0.1 mL) were pipetted into the tubes and allowed to warm to 37°C for exactly 30 seconds. Then, 0. I mL prewarmed CaC12 solution was pipetted into each tube and rapidly mixed. The clotting time was determined by the manual tilttube method, measured from the point of addition of CaCI2. These assays were performed in duplicate.
Automated soluble TF clotting assays were performed using a coagulometer (Automated Coagulation Laboratory model ACL3OO+ from Instrumentation Laboratories, Lexington, MA) as follows: The instrument was operated in research mode, and sample volumes per assay (plasma, soluble TF reagent, and 25 mmol/L CaC& solution) were 50 pL each. Settings were: 64 seconds activation time; 1 second inter-ramp interval; 0 seconds delay; 250 seconds acquisition time; 1,200 rpm rotor speed. Before each performance of the soluble TF clotting assay, the instrument was cleaned with 0.1 N HCl as recommended by the manufacturer to eliminate carry-over of plasma or thromboplastin from previously conducted assays. Data were collected on an IBM microcomputer and analyzed using the Windows Research Software supplied with the coagulometer (Instrumentation Laboratories), with clotting times determined by absorbance threshold (threshold set at 6.5% of baseline). For comparison, some assays were performed using a Fibrometer (Becton Dickinson).
Soluble TF reagent.
For personal use only. Added FVlla, ng/ml The same data from (C) replotted after correcting the FVlla concentrations for the endogenous FVlla content (for factor IX-deficient plasma this was 0.12 ng/mL FVlla; for normal plasma, 0.89 ng/mL FVlla). Note that all the points now lie on the standard curve generated using the FVII-deficient plasma.
Standard curves for calibration of the soluble TF clotting assay for FVIIa were prepared using citrated, FVII-deficient plasma containing varying final concentrations of either recombinant or plasmaderived human FVlla (by serial dilution) and performing the clotting assays in either manual or automated mode as described above. The clotting times were plotted versus the concentration of FVIIa on log-log scales, and a polynomial curve was fit to the data by regression analysis using Slide Write Plus version 4.1 (Advanced Graphics Software, Sunnyvale, CA) run on an IBM-compatible microcomputer. The concentrations of FVIIa in unknown plasma samples were calculated from the measured clotting times by performing an iterative solution to the polynomial equation fit to the clotting times of the FVIIa standards (using a computer program written in Turbo Pascal). These values were then multiplied IO-fold to correct for the dilution with FVII-deficient plasma. A new standard curve was prepared for each lot of soluble TF reagent and for each assay configuration. Values for FVIIa levels among various sub-groups of the study population are reported as mean -C standard deviation. Values for statistical significance (P) were from Student's t-test.
FVII:C assays used Immunoadsorbed Factor VI1 Reference Plasma (Human) from Baxter Healthcare Corp (Miami, FL) and were performed on the ACL300+ coagulometer (Instrumentation Laboratories) according to the manufacturer's directions. Fibrinogen levels and prothrombin times were performed using a Other assays.
PT-Fibrinogen Reagent Kit (Instrumentation Laboratories) with the ACL300+ coagulometer according to the manufacturer's directions.
RESULTS

Dependence of clotting time on FVIIa concentration.
s T F~.~~~, a soluble mutant form of TF consisting only of the extracellular domain, was previously reported to retain cofactor function when tested with purified FVIIa, factor x, and phospholipid vesicles. 24 We recently demonstrated that s T F~-~~~ has selectively lost the ability to promote the activation of FVII to FVIIa.9 Therefore, if conversion of FVII to FVIIa during clotting is indeed dependent on this function of wild-type TF, then s T F~-~~~ should clot plasma based on its pre-existing content of FVIIa, and not on its content of zymogen FVII. In the present study, we have compared the ability of wild-type TF versus sTF2.219 to promote clotting of human plasma to which varying amounts of purified FVIIa had been added (Fig 1, A and B) . The clotting time of normal human plasma initiated by wild-type TF was relatively insensitive to the presence of added FVIla (Fig 1A) . In contrast, the clotting times of human plasma initiated by a mixture of S T F~.~,~ and phospholipid vesicles exhibited a very strong dependence on FVIIa levels from approximately 1 ng/mL to 10 pg,/mL added FVIIa (Fig 1B) . Therefore, s T F~.~,~ appeared to fit the requirements outlined above for a mutant TF that could be used to develop a new clotting assay specific for plasma FVIIa.
exhibited a plateau at concentrations of added FVIIa that were less than approximately 1 ng/mL (Fig 1B) . A likely explanation for this result was that the endogenous FVIIa level of the plasma was on the order of 1 ng/mL. To develop a ~T F~.~~~-b a s e d clotting test capable of measuring absolute FVIIa levels, it was necessary to find a means of calibrating the assay. In theory, this could be accomplished by preparing a standard curve of clotting time versus FVIIa concentration using human plasma that contained little or no baseline FVIIa (ie, FVIIa-deficient plasma). It was reasoned that plasma deficient in FVII should also exhibit correspondingly low levels of plasma FVIIa. When the soluble TF clotting tests were performed with FVII-deficient plasma supplemented with FVIIa, no evidence of plateau in the clotting curve was seen at levels of added FVIIa down to 10 pg/mL (Fig IC) . This indicated that FVII-deficient plasma supplemented with varying concentrations of FVIIa could be used to prepare a standard curve for calibration of the assay. Furthermore, it indicated that the assay would have a remarkable sensitivity range (10 pg/mL to 10 pg/mL FVIIa).
Soluble TF clotting times of normal and hemophilic plasmas (supplemented with FVIIa) exhibited the previously encountered leveling off of the clotting curves at low levels of added FVlIa (Fig 1C) . The clotting times of these plasmas determined in the absence of any added FVIIa were used to calculate the endogenous levels of FVIIa by reference to a standard curve prepared from parallel clotting time determinations of FVII-deficient plasma supplemented with purified FVIIa. For the normal and hemophilic plasmas in Fig  1, the endogenous levels of FVIIa were calculated to be 0.89 and 0.12 ng/mL, respectively. These baseline FVIIa values were used to recalculate the actual final concentrations of FVIIa in the plasmas, and the clotting curves were replotted (Fig 1D) . After recalculation, the points were found to fit well to the standard curve obtained with FVII-deficient plasma, as would be predicted if the assay were a sensitive and specific measure of plasma FVIIa levels.
The clotting assays described above were conducted in polystyrene test tubes to avoid contact activation. When the assays were performed in unsiliconized borosilicate glass test tubes, shorter clotting times were consistently observed for normal plasma compared with FVII-deficient at all concentrations of added FVIIa tested. Furthermore, data points recalculated to account for "endogenous" FVIIa levels in this case deviated from the curve prepared using FVII-deficient plasma (data not shown). Activation of the contact pathway by glass likely resulted in the conversion of some plasma FVII to FVIIa, which then interfered with the assay. This underscored the necessity of using plastic tubes for the clotting test.
Manipulation of assay sensitivity. Clotting times of plasma using s T F~.~~~ and phospholipid as the procoagulant were found to depend on the concentration of s T F~-~~~, with
The clotting time curve of normal plasma with clotting times approaching a minimum at approximately 2 to 5 pmol/L sT&-219 (Fig 2A) . This suggested that sensitivity of the soluble TF clotting assay toward FVIIa could be manipulated simply by changing the s T F~-~~~ concentration to obtain a convenient range of clotting times with a given expected range of FVIIa levels. Fig 2B shows FVlla, ng/ml For personal use only. on October 22, 2017. by guest www.bloodjournal.org From normal individuals (Fig 2C) . Assay sensitivity could also be adjusted by varying the phospholipid concentration, which resulted in a family of parallel clotting curves similar to those of Fig 2C (data not shown) . Furthermore, several different types of phospholipid vesicles were tested, including vesicles prepared from purified phosphatidylcholine and phosphatidylserine, from mixed brain phospholipids, and a commercial rabbit brain cephalin preparation marketed for use in the partial thromboplastin time test. All gave equivalent results, indicating that the precise nature of the phospholipid vesicle preparation appeared not to be important. If zymogen FVII was indeed not converted to FVIIa during clotting induced by it was reasoned that reconstituting FVII-deficient plasma with purified FVII to the levels encountered in normal plasma should have no effect on the observed clotting time. The preparation of FVII used contained undetectable FVIIa by sodium dodecyl sulfate (SDS)-polyacrylamide gel analysis.' However, because even highly purified FVII contains traces of FVIIa,'* it was necessary to measure the level of FVIIa present in our preparation of recombinant FVII. Therefore, trace contamination by FVIIa was assessed as previously described: taking advantage of the fact that enhances the amidolytic activity of FVIIa under conditions where FVII is not converted to FVIIa. First, the amidolytic activity of the recombinant FVII (at 30 to 3,000 nmol/L) was measured in the presence of 4 pmol/L S T F~.~~~. The rate of chromogenic substrate hydrolysis per nanomolar FVII was then compared with a standard curve of the rate of substrate hydrolysis versus FVIIa concentration that had been prepared by performing the identical procedure, except that varying concentrations of purified FVIIa were used, as previously described.' From this analysis, it was calculated that the recombinant FVII preparation contained 0.475 +-0.033 mole percent FVIIa. Recombinant FVII was then added to congenital €341-deficient plasma to a final concentration of 500 ng/mL, and clotting times were determined using soluble TF reagents composed of 1 pmol/L s T F~-~,~ and either 2X RBC or 100 pmol/L PCPS vesicles. The clotting times (36.7 and 38.7 seconds, respectively) determined using an automated coagulometer were then converted to FVIIa concentrations by comparison with standard curves of soluble TF clotting times that had been prepared by adding known concentrations of FVIIa to the FVII-deficient plasmas (resulting in standard curves similar to those of Fig 2C) . The clotting times for the FVII-supplemented, FVII-deficient plasma obtained with the two soluble TF reagents corresponded to FVIIa concentrations of 2.5 and 2.2 ng/mL, respectively. Expressed as percent of added FVII, these values corresponded to 0.50% and 0.4476, respectively, which agree well with, and more importantly are not significantly higher than, the value of 0.475% FVIIa determined by the amidolytic assay. This provides independent evidence that significant amounts of zymogen FVII were not converted to FVIIa when clotting was promoted by the soluble TF reagent.
Configuration ofthe soluble TF clotting assay for FVIIa, stability of FVIIa in citrated plasma, and cold activation of FVZI. For the remainder of this study (unless otherwise
Lack of contribution of zymogen FVII to clotting times.
noted), the soluble TF clotting assay for measuring FVIIa levels was performed using a soluble T F reagent consisting of 1 pmol/L s T F~-~~~ and 2X RBC. Test plasma samples were routinely diluted IO-fold with FVII-deficient plasma. Although the assay can be performed on undiluted plasma samples, this was not routinely used because of concern that individual variation in plasma components other than FVIIa (such as levels of factor X, prothrombin, fibrinogen, various inhibitors, etc) might have an influence on the observed clotting times. Therefore, diluting the test plasma samples with FVII-deficient plasma would mean that 90% of the levels of all clotting factors will be contributed by the FVII-deficient plasma; therefore, this should diminish the effect of variation in levels of factors other than FVIIa. Standard curves were generated using FVII-deficient plasma supplemented with varying concentrations of FVIIa (typically 0.03, 0.3, 3, and 30 ng/mL final concentration). Both immunodepleted and congenital FVII-deficient plasma were found to give equivalent results, as did the use of either plasma-derived or recombinant FVIIa for generation of standard curves. In all cases, the same lot of FVII-deficient plasma used for dilution of test plasmas was also used for generating the corresponding FVIIa standard curve.
It was of interest to determine the stability of plasma FVIIa in regard to the FVIIa assay. In a variety of different experiments, plasma samples were assayed immediately following collection, after storage at -7O"C, or after incubation at ambient temperature for 2 hours in plastic test tubes. The results agreed within 10% of the initial values (data not shown).
The FVII activity level of plasma samples has been reported to increase during storage at cold temperatures (above freezing but significantly below room temperature), in a process known as cold activation. Cold activation of plasma is thought to reflect the slow conversion of plasma FVII to FVIIa mediated by the contact pathway of blood c l~t t i n g .~~.~~ This process was examined with the new soluble TF assay, using citrated human plasma from three volunteers that had either been assayed immediately following collection, or incubated 5 hours at room temperature, 37"C, or on ice ( Table I) . The effect of incubation of these plasmas in polystyrene, untreated borosilicate glass, or siliconized glass containers was also assessed. Incubation in plastic or siliconized glass tubes at any of the three temperatures in general did not result in significant increases in measured plasma FVIIa levels, with the exception of donor no. 1, whose measured FVIIa levels increased from 1.2 to 2. I ng/mL following a 5-hour incubation on ice in siliconized glass. However, when these plasma samples were incubated in untreated glass tubes marked elevations in measured FVIIa levels were observed for all three temperatures. This effect was most striking in samples that had been incubated in untreated glass containers on ice, resulting in up to 12-fold increase in FVIIa concentration.
Eflect of heparin on determination of FVIIa levels.
Because it may be desirable to determine FVIIa levels in individuals who have received heparin treatment, it was of interest to examine the potential effect of heparin on measured FVIIa levels. Accordingly, heparin was added at varying concentrations to a citrated plasma sample, and the soluble TF clotting assay was performed. As can be seen from FVlla levels (in ng/mL) were measured with the soluble TF assay using citrated plasma samples that were assayed immediately after collection (Initial), or following incubation for 5 hours at the specified temperatures (ambient temperature was approximately 22°C). Siliconized Glass, Vacutainer blood collection tubes; Untreated Glass, borosilicate glass test tubes (both had been rinsed with deionized water and air-dried before use).
2, addition of heparin to the test plasma at levels up to 1 U/ mL had no significant effect on the observed FVIIa levels. Thus, although high levels of heparin (5 U/mL) interfered with the assay, therapeutic levels of heparin (0.1 to 0.5 U/ mL in plasma) should not interfere with determining FVIIa levels using the new assay. The relative insensitivity of the assay to heparin is probably caused, in part, by the 10-fold dilution of the test plasma with FVII-deficient plasma.
To establish the precision of the new soluble TF clotting assay for FVIIa, the assay was performed five times per day on 10 successive days using aliquots of citrated plasma derived from a single collection from a single donor (stored frozen at -70°C). The overall mean plasma FVIIa for this donor was found to be 4.14 ng/mL, with coefficients of variation for within-day and between-day variability of 2.2% and 8.1%, respectively.
Day-to-day variation in FVIIa levels were determined on plasma samples obtained from three donors on three sequential days ( Table 3) . One donor (no. 1) had low but relatively constant levels of measured FVIIa on all 3 days, whereas another donor (no. 2 ) had higher levels that increased somewhat (by 38%) on the third day. The third donor had levels that approximately doubled on day 3. This donor had a history of peptic ulcer, and experienced an episode of acute gastritis on day 3; however, the significance of this condition to the increase in measured FVIIa levels is unknown.
It was important to address the possibility that plasma FVIIa could be the result of a phlebotomy artifact. It was conceivable, for example, that artifactual generation of FVIIa occurred during blood drawing (as a consequence of transient activation of the clotting cascade at the site of insertion of the needle), and that this accounted for the measured FVIIa. Immediately before measuring FVlla levels, heparin was added to aliquots of a citrated human plasma to the indicated final concentrations.
Individual variation in measured FVIIa levels.
Ifthis hypothesis were correct, it would be expected that variation in FVIIa levels would be random, and not a characteristic of a given individual. To test the source of individual variation in plasma FVIIa levels, samples from the donors in Table 3 were obtained by phlebotomy simultaneously from both the left and right arms (day 3). The measured FVIIa levels of the duplicate samples for donor nos. 1 and 2 were identical, while the levels measured in the samples from donor no. 3 differed by 7.4% from each other. In additional experiments, FVIIa levels were determined in several plasma samples taken from the first and second syringes obtained from the same needle puncture. Differences between FVIla levels in the first and second syringes was always less than 10% (data not shown). Therefore, differences in FVIIa levels appear to be a characteristic of the individual donors, and are highly unlikely to be caused by random FVIIa generation during phlebotomy.
Variation in FVIIa levels among individuals in a study
population. In an initial assessment of individual variation of plasma FVIIa levels, a population study was undertaken in which FVIIa concentrations were measured in plasma samples obtained from 200 healthy donors. Statistics on the age distribution, smoking status, and use of oral contraceptives of individuals in the study population is given in Table  4 . Excluding pregnant women, the overall mean plasma FVIIa concentration for the population (188 donors) was 3.58 ngl mL with a standard deviation of 1.44 ng/mL. The range of FVIIa concentrations was very large, varying nearly 17-fold from a low of 0.5 ng/mL to a high of 8.4 ng/mL. Expressed as percentage of the mean, this corresponds to a range of FVIIa levels of 14.0% to 235% of the mean value. Exclusion of smokers and users of oral contraceptives from analysis left a population of 87 individuals with a mean FVIIa concentration of 3.13 ng/mL and a standard deviation of 1.44 ngl mL. The observed range of FVIIa concentrations in this subpopulation was 0.5 ng/mL to 6.9 ng/mL, corresponding to a range of 13.4% to 186% relative to the mean value. Variations in FVIIa levels are depicted in Fig 3, sorted according to sex, smoking status, and use of oral contraceptives. In this study population (excluding pregnant women), no significant difference between FVIIa levels of males versus females was observed. Males had a mean FVIIa level of 3.8 k 1.37 ng/mL, whereas females had a mean of 3.64 f 1.5 I ng/mL. In addition, no significant difference was observed when the study population was divided according to smoking status (smokers, mean plasma FVIIa of 3.55 k 1.41 ng/mL; nonsmokers, 3.60 * 1.46 ng/mL; P > .5) or use of oral contraceptives (oral contraceptive users, mean plasma FVIIa of 3.3 1 k 1.42 ng/mL; not oral contraceptive users, 3.50 k I .52 ng/mL; P > .25). Indeed, when FVIIa levels were compared among all the respective sub-groups, the only difference that approached statistical significance was between female nonsmokers who did or did not use oral contraceptives (oral contraceptive users, mean plasma FVIIa of 3.03 f I .4 1 ng/ mL; not oral contraceptive users, 3.64 k 1.51 ng/mL; P = .06). However, because the mean ages differed substantially between the two sub-groups (nonsmoking women who did or did not use oral contraceptives), it is possible that the difference in mean FVIIa levels between the two could reflect the difference in mean age rather than use of oral contraceptives. As can be seen from Fig 4, there was a significant correlation between FVIIa levels in both males and females with increasing age ( r = .40, P = .009, and r = .34, P = .03, respectively).
Correlation between FVIIa levels and other parameters of the clotting system. The FVII:C assay is thought to measure an aggregate of both FVII and FVIIa in plasma. Therefore, it was of interest to compare FVI1:C levels to FVIIa levels (Fig 5) . A positive correlation between FVI1:C and FVIIa levels was observed both in males and females (r = 32, P < respectively). However, for a and r = 34, P < given FVI1:C level, FVIIa varied by as much as 2.5-fold, and only 50% of the points fell within the 95% confidence interval of the correlation (Fig 5) .
As depicted in Fig 6 , no significant correlation was observed between plasma fibrinogen and FVIIa levels in males or fe- Relationship between plasma FVlla levels and age for normal males and females (nonsmokers, not using oral contraceptives). The study population is described in Table 4 , and FVlla levels were determined as described in the legend to . The study population is described in Table 4 , and FVlla levels were determined as described in the legend to males ( r = .009, P = .95, and r = -.007, P = .96, respectively). However, there was a negative correlation between prothrombin time and FVIIa levels (Fig 7) in both males and females (r = -.70, P < FVIIa levels were determined in 12 healthy pregnant women, none of whom smoked. Figure 8 depicts a comparison of FVIIa levels between these pregnant women and age-matched, nonpregnant women (nonsmokers who were not taking oral contraceptives). Pregnant women had mean FVIIa levels of 5.35 k 2.06 ng/mL. This was significantly higher than nonpregnant control women, who had mean FVIIa levels of 3.13 k 0.74 ng/mL The effect of oral anticoagulant therapy on plasma FVIIa was and r = -.72, P < FVIIa levels and pregnancy.
(P = .002).
Efect of oral anticoagulant therapy on FVIZa levels. Plasma FVlla, ng/ml Fig 6 . Lack of correlation between plasma fibrinogen and FVlla levels in normal males and females (nonsmokers, not using oral contraceptives). The study population is described in Table 4 , and FVlla levels were determined as described in the legend to Plasma FVlla, ng/ml Fig 7. Relationship between prothrombin time and plasma FVlla levels in normal males and females (nonsmokers, not using oral contraceptives). The study population is described in Table 4 , and FVlla levels were determined as described in the legend to FVlla levels in nonsmoking, pregnant women compared with age-matched, nonsmoking women (not using oral contraceptives). Plasma samples were obtained during uncomplicated pregnancies from 12 healthy women (P) ranging in age from 18 to 38 years old, while plasma FVlla values for age-matched control women (NP) were taken from the study population described in Table 4 .
Samples were obtained during the first (A), second (o), or third (0) trimester of pregnancy. All FVlla levels were determined as described in the legend to Fig 3; values for the pregnant women were determined at the same time, using the same batch of reagents, as the nonpregnant women. greatest prolongation (which generally took 7 to 10 days or more).
DISCUSSION
Although the existence of low levels of FVIIa in plasma was postulated," plasma FVlIa has not been measurable directly because of limitations in existing assay techniques. The main technical problem has been that T F strongly promotes the conversion of FVII to FVIIa, meaning that both FVII and FVIIa contribute to the FVII:C a~say.~-','~ However, we have recently demonstrated that a soluble mutant form of T F has selectively lost the ability to promote activation of FVII to FVIIa.9 Because soluble mutant TF retains the ability to serve as the cofactor for FVIIa-catalyzed activation of factor X,24 this form of T F should be ideal in developing a clotbased assay for plasma FVIIa that is insensitive to the presence of zymogen FVII. In the present study, we have shown that replacing T F with s T F~.~~~ in a simple clotting assay (performed in a manner similar to existing assays of FV1I:C) renders the assay extremely sensitive to the presence of preexisting FVIIa in plasma, and free of detectable interference from FVII. The effective range of the assay is very large, extending from 10 pg/mL to as much as 10 pg/mL FVIIa. Control experiments established that artifactual generation of FVIIa during phlebotomy, if it took place, did not contribute significantly to the measured FVIIa levels.
Citrated plasma has been known to undergo "cold activation" if stored at temperatures just above freezing, especially in glass container^.^^,^^ Cold activation is reflected in an increase in FVI1:C levels, and has been hypothesized to be a consequence of activation of plasma FVII via the contact pathway of blood clotting. In this study, we have measured directly the increase in FVIIa levels during storage of plasma samples on ice in glass containers. Therefore, the new FVIIa assay should be useful in studying the process of cold activation in greater detail.
Elevated plasma FVII:C levels, along with elevated plasma fibrinogen, have been found to be significant predictors of risk of ischemic heart disease and cardiovascular death in epidemiologic studies.14-16 However, FVII:C assays have been performed differently in different laboratories, and the degree of sensitivity of the FVII:C assay to FVII versus FVIIa is thought to vary depending on assay configuration." Indeed, it is controversial whether or not the important factor in elevated FVII:C levels is elevation in plasma FVIIa per se, or elevation in total FVII Thus, it would clearly be desirable to evaluate FVII and FVIIa levels separately. Total plasma FVII can already be measured with existing technology, either by enzyme-linked immunosorbent assay (ELISA) methods,2 or by activity assays in which the bulk of FVII is converted to FVIIa, such as FVII amidolytic assays (discussed by Hoffman et all'). The ratio of FVII:C to total FVII mass has been used to try to obtain an indication of the degree of activation of plasma FVII.17-19 However, this method relies on assumptions concerning what FVII:C is measuring, is subject to variability in sensitivity of FVII:C to FVIIa, and does not yield an absolute measure of FVIIa levels. The novel assay described in this study now provides the means to rapidly and directly determine plasma FVIIa levels, and therefore should be useful in answering the question of the role of FVIIa per se as a predictor of risk in disease.
Although an extensive epidemiologic study of the association of disease risk with FVIIa levels is clearly outside the scope of the present communication, we undertook an initial population study to determine the degree of individual variation in FVIIa levels, and to examine potential correlations between FVIIa levels and such parameters as age, sex, smoking, use of oral contraceptives, and pregnancy. This study confirms the earlier prediction that plasma might normally contain trace levels of pre-existing FVIIa," and furthermore provides previously unavailable quantitation of plasma FVIIa levels. Plasma FVIIa values were found to vary substantially between individuals-among 188 volunteers' FVIIa levels varied nearly 17-fold, from a low of 0.5 ng/mL to a high of 8.4 ng/mL, with a mean of 3.58 +. 1.44 ng/mL. Taking the mean concentration of total plasma FVII + FVlla in humans to be 470 ng/mL,2 the mean plasma level of FVIIa found in this study would represent 0.76% of the total FVII mass. No significant differences in FVIIa levels were observed between men and women, nor was there a clear correlation between FVIIa levels and smoking status or use of oral contraceptives in this population. A significant correlation between FVIIa levels and increasing age was found, although substantial For personal use only. on October 22, 2017. by guest www.bloodjournal.org From variation between individuals was observed even within age groups.
Based on a preliminary presentation of our new assay in abstract form, 31 Wildgoose et a13' used the soluble T F assay to measure FVIIa levels in a normal and hemophilic population, reporting a mean FVIIa level in normal individuals (4.34 k 1.57 ng/mL) similar to that found in the present study. Wildgoose et a132 also found FVIIa levels to be slightly decreased in severe factor VIII-deficient patients, and substantially decreased in severe factor IX-deficient patients. However, their study did not report the age distribution of the study populations; given the age dependence of FVIIa levels found in the present study, it would be important to ensure that hemophilic patients are compared with an agematched control group.
Potential correlations between plasma FVIIa levels and other parameters of the clotting system were investigated in the present study. FVIIa levels exhibited no significant correlation with plasma fibrinogen. This is interesting in light of epidemiologic studies associating both elevated plasma fibrinogen and FVII:C levels with increased risk of heart disease, and the fact that fibrinogen levels have been observed to be increased in smokers versus nonsmokers (reviewed by HultinI6 and Thus, if plasma FVIIa is associated with risk of heart disease, it would constitute an independent risk factor relative to plasma fibrinogen levels, smoking, or use of oral contraceptives. This opens the possibility that combined risk estimates of fibrinogen levels (or smoking, contraceptive use, etc) and FVIIa levels may constitute a more powerful means of determining risk of thrombosis.
Plasma FVIIa levels exhibited a relatively weak but positive correlation with the results of the FV1I:C test. This was expected, given that FVII:C is thought to measure both FVII and FVIIa in plasma. FVIIa levels were found to be negatively correlated with prothrombin times (as were FVII:C levels; data not shown). If plasma FVIIa serves a priming function in TF-mediated triggering of the clotting cascade, prothrombin times should be shortened in the presence of increasing FVIIa. Indeed, previous studies have shown that adding purified FVIIa to plasma results in shortening of the prothrombin time.34 As with the relationship between FVIIa levels and FVII:C, however, the correlation was not perfect. This is also not surprising, considering that the prothrombin time is sensitive to variation in the levels of several different clotting factors.
FVIIa levels decreased rapidly and dramatically in patients with deep vein thrombosis as they underwent oral anticoagulation therapy. If FVIIa proves to be a marker of risk of additional thromboses, measuring FVIIa levels might be an effective means of monitoring warfarin dosage in such pati e n t s.
Pregnancy has previously been reported to be associated with substantial increases in FVII:C levels,30~35*36 and the question has been raised as to a possible association between high plasma FVII activity and fetal growth retardati~n.~' In the present study, we have found that FVIIa levels are significantly increased during normal pregnancy.
The new assay will now permit direct analysis of the role of FVIIa as a risk predictor for thrombosis. In particular, it will be important in future studies to evaluate the role of FVIIa per se for conditions associated with elevated FVII:C levels, including risk of ischemic heart disease and fetal growth retardation. In addition, it will be important to determine the diurnal variation in FVIIa and the effect of serum triglyceride levels16,17,19,37,38 on the determination of FVIIa using the new assay. Furthermore, the new assay could be used to measure the effective plasma dose of FVIIa in individuals receiving recombinant FVIIa therapy for bleeding disorders.'* It will also be of interest to compare FVIIa levels in a variety of clinical and experimental settings to measurements of the degree of in vivo activation of other proteases of the clotting cascade, such as assays that measure plasma levels of proteaseinhibitor complexes, F1+', or activation peptides released from various other clotting factors.20*2'
